E-Mail
New York, NY (May 6, 2021) Researchers have finally cracked the code of a bewildering pediatric disease that sets off a characteristic cytokine storm a harmful immune system overaction resembling one that arises in COVID-19 cases and can lead to catastrophic multisystem organ failure or neurodegeneration. Their study, which identifies the cause of the cytokine storm and possible treatments, was published in
Nature Medicine in May.
The mystery of this disease, Langerhans-cell histiocytosis (LCH), runs deep. Its symptoms vary widely, and LCH has the ability to infiltrate almost any organ system, leaving most patients with long-term consequences that may include a devastating neurodegenerative syndrome that can arise years after other symptoms have abated.
Alliance for Cancer Gene Therapy Summit 2021 Features World Renowned Cancer Researchers Advancing Solid Tumor Breakthroughs
Share Article
James P. Allison, PhD, Carl H. June, MD and Siddhartha Mukherjee, MD Keynote April 29 Summit
Nobel Laureate James P. Allison, PhD, Carl H. June, MD and Pulitzer-prize winning author Siddhartha Mukherjee, MD will be the keynote speakers at the virtual Alliance for Cancer Gene Therapy Summit
It’s so rare to have the opportunity to hear from the world’s top cancer researchers, biotechs, investors and patients all in the same room STAMFORD, Conn. (PRWEB) April 16, 2021 April 29 marks a pivotal moment in cancer research when the world’s brightest minds come together to discuss how to translate the success of CAR T-cell therapies for blood cancers into successful cell and gene therapies for the most complex and deadly solid tumor cancers. The scientists and companies driving
Experts to discuss advanced cancer cell and gene therapies at Summit 2021
April 29 marks a pivotal moment in cancer research when the world s brightest minds come together to discuss how to translate the success of CAR T-cell therapies for blood cancers into successful cell and gene therapies for the most complex and deadly solid tumor cancers.
The scientists and companies driving the latest advances in cancer cell and gene therapy will gather online for a virtual Summit with the Alliance for Cancer Gene Therapy, who envision a cancer free future and want to change the C-word from Cancer to Cure. The Summit is open to the public, to medical professionals, scientists and companies interested in cell and gene therapy to fight cancer. To register for the Summit, visit acgtfoundation.org.
A scientific team led by Brian Brown, PhD, Professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has been awarded $500,000 from Alliance for Cancer Gene Therapy to advance a promising immunotherapy approach to fight lung cancer and other solid tumor cancers.
E-Mail
IMAGE: Brian Brown, PhD, professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has. view more
Credit: Mount Sinai
A scientific team led by Brian Brown, PhD, Professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has been awarded $500,000 from Alliance for Cancer Gene Therapy (ACGT) to advance a promising immunotherapy approach to fight lung cancer and other solid tumor cancers.
Despite some amazing successes, not all patients respond to current immunotherapies. Dr. Brown notes that one cell type that appears to be responsible for poor responses to immunotherapy against solid tumors is called a macrophage. As part of the natural immune system, macrophages typically protect patients from infections, but tumors can reprogram mac